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Abstract
Objectives. With a rapidly growing list of candidate immune-
based cancer therapeutics, there is a critical need to generate
highly reliable animal models to preclinically evaluate the efficacy
of emerging immune-based therapies, facilitating successful
clinical translation. Our aim was to design and validate a novel
in vivo model (called Xenomimetic or ‘X’ mouse) that allows
monitoring of the ability of human tumor-specific T cells to
suppress tumor growth following their entry into the tumor.
Methods. Tumor xenografts are established rapidly in the greater
omentum of globally immunodeficient NOD-scid IL2Rcnull (NSG)
mice following an intraperitoneal injection of melanoma target
cells expressing tumor neoantigen peptides, as well as green
fluorescent protein and/or luciferase. Changes in tumor burden, as
well as in the number and phenotype of adoptively transferred
patient-derived tumor neoantigen-specific T cells in response to
immunotherapy, are measured by imaging to detect
fluorescence/luminescence and flow cytometry, respectively.
Results. The tumors progress rapidly and disseminate in the mice
unless patient-derived tumor-specific T cells are introduced. An
initial T cell-mediated tumor arrest is later followed by a tumor
escape, which correlates with the upregulation of the checkpoint
molecules programmed cell death-1 (PD-1) and lymphocyte-
activation gene 3 (LAG3) on T cells. Treatment with immune-based
therapies that target these checkpoints, such as anti-PD-1 antibody
(nivolumab) or interleukin-12 (IL-12), prevented or delayed the
tumor escape. Furthermore, IL-12 treatment suppressed PD-1 and
LAG3 upregulation on T cells. Conclusion. Together, these results
validate the X-mouse model and establish its potential to
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preclinically evaluate the therapeutic efficacy of immune-based
therapies.
Keywords: cancer immunotherapy, checkpoint blockade,
melanoma, patient-derived xenograft, T cells
INTRODUCTION
The emergence of cancer immunotherapy in the
last decade, illustrated by advances in adoptive
cellular therapy and immune cell-targeted
monoclonal antibody (mAb) therapy, has resulted
in a vast improvement in the overall survival of
patients with advanced-stage cancer.1 This has
understandably generated a lot of interest in the
field, resulting in a plethora of candidate
immunotherapeutic targets and therapeutics for
preclinical testing, which is usually carried out in
animal models. Successful translation of preclinical
results is predicated upon how clinically predictive
these models are. Findings that over 90% of new
drugs are ineffective in clinical trials2,3 suggest
that the inefficiency of current preclinical models
contributes towards the low translation rate.
There is therefore an unmet critical need for the
design and validation of animal models to
preclinically evaluate the efficacy of immune-
based therapies.
While cell line-derived xenograft models are
more commonly used for initial phases of drug
development and toxicity studies, patient-derived
xenograft (PDX) models, which involve
implantation of cancer tissue from individual
patients into immunodeficient mice, are more
reliable models for preclinical research. Starting
from the first successful engraftment of human
tumors into immunodeficient mice over 30 years
ago,4 a number of xenograft models have been
reported5–8 with attempts made to assess the
efficacy of immunotherapies.7,9–12 More recently,
humanised NOD-scid IL2Rcnull (NSG) mice (HuNSG)
mice were developed by implanting
hematopoietic stem and progenitor cells into
conditioned NSG mice, resulting in the generation
of multiple human immune cells including T cells,
B cells, plasma cells, dendritic cells and myeloid
cells.13–15 These HuNSG mice, which develop a
partially functional immune system,7,13,16
overcome some limitations of the earlier PDX
models. While this approach has great potential
for evaluating immune-based strategies,17,18 it is
logistically challenging, requiring up to 12 weeks
to generate these functional immune cells, a
further 60 days to establish tumor xenografts and
several additional weeks to assess the response of
the T cells to tumors. In general, PDX models,
including the humanised mouse model, have been
logistically challenging and difficult to standardise
as it has not been possible in most cases to
control the number of tumor-specific T cells in the
xenografts or to confirm and to identify the
tumor specificity of the T cells in the model.17,18
Here, we report a novel mouse model, the
Xenomimetic mouse (X-mouse) model, established
using patient-derived tumor-specific T cells and
GFP+ melanoma tumor target cells expressing
melanoma patient-derived tumor neoantigen
peptides in the context of matched HLA. The use
of a defined number of tumor target cells and
adoptively transferred tumor antigen-specific
patient-derived CD8+ T cells makes it possible to
monitor human anti-tumor T-cell responses in a
controlled environment in the X-mouse model.
We validate the ability of our model to rapidly
evaluate the therapeutic efficacy of immune-
based therapies designed to enhance the anti-
tumor potential of tumor-specific T cells following
their entry into the tumor microenvironment. We
conclude that the X-mouse model represents a
reliable preclinical platform to evaluate the
efficacy of new immune-based therapies for
cancer as standalone treatments or combination
therapies.
RESULTS
Generation of the Xenomimetic (X) mouse
model
The X-mouse model consists of two cellular
components: melanoma tumor target cells and
tumor-specific T cells. These cells were generated
and characterised previously as part of a
neoantigen vaccination clinical trial with
melanoma patients.19,20 Tumors resected from
stage III melanoma patients enrolled in the trial
were exome and transcriptome sequenced to
identify expressed tumor-specific mutated
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proteins. In silico and algorithmic analysis was
performed to predict high-affinity HLA-A*02:01
binding amino acid substituted peptides arising
from identified mutated proteins. Synthetic
peptides were manufactured and used to
immunise melanoma patients with peptide-pulsed
autologous dendritic cells as part of a
personalised neoantigen vaccination. Each
melanoma patient received a unique set of
peptides selected based on tumor mutational
profile. After vaccination, CD8+ T cells specific for
amino acid substituted peptides were isolated
from patients’ leukapheresis products, expanded
in vitro and sorted using custom HLA/peptide
dextramers to obtain 70–95% enriched
neoantigen-specific T-cell populations. Tumor-
specific cells used in our study are TKT R438W and
TMEM48 F169L, derived from patient MEL21, and
a detailed characterisation of these T cells has
been previously reported19 (Supplementary
figure 1).
To generate tumor target cells, DM6, an HLA-
A*02:01+ melanoma cell line, was transfected with
tandem minigene constructs (TMCs) encoding the
mutated neoantigen peptides from patient MEL21
(DM6-Mut) or the corresponding wild-type
peptides (DM6-WT). The TMCs were cloned into
vectors that encode GFP, which allows easy
detection of tumor cells.19 The expression of the
respective peptide in the context of HLA-A*02:01
as well as GFP in DM6-WT and DM6-Mut cells was
confirmed.19
The animal component of the X-mouse model is
a strain of globally immunodeficient mice, i.e. the
NSG mice. Intraperitoneal (i.p.) injection of DM6
cells into NSG mice results in their rapid and
preferential engraftment to an anatomically well-
defined site, the greater omentum. The greater
omentum is a small strip of well-vascularised fatty
tissue located between the stomach, pancreas and
spleen that has been shown to support the
growth of multiple patient-derived tumors
including ovarian tumors9 and lymphomas.21
Pockets of DM6 tumor cells easily distinguishable
from the omental fat cells are visible by
haematoxylin and eosin (H&E) staining of omental
sections as early as 1 day following injections, and
these tumors grow rapidly over time (Figure 1a).
More importantly, the presence of GFP as a
reporter enables scanning of whole mounts of the
entire omentum under a fluorescence microscope
to view and accurately quantify (GFP+) tumor
burden post-mortem (Figure 1b).
To enable detection and quantitation of tumor
growth and spread across multiple organs, and
also to track tumor growth kinetics in the same
animals, we transduced DM6-WT and DM6-Mut
cells with firefly luciferase (Supplementary
figure 2). Live imaging of mice-bearing luciferase-
expressing DM6 cells following the injection of
luciferin allows determination of tumor burdens
in the same animals over time. As observed in the
omentum, robust growth of DM6 cells was seen in
these mice with a concomitant spread over time
(Figure 1c and d).
After establishing the growth of tumor in the
omentum, we sought to determine whether
tumor-specific TKT R438W cells injected i.p. can
localise and survive in the greater omentum. We
detected CD3+ T cells 6 days following their i.p.
injection, establishing their presence in the
omentum (Figure 1e). Additionally, we detected
the presence of viable antigen-specific CD8+ T cells
(dextramer+CD3+CD8+ cells) in day 25 DM6-Mut
xenografts, establishing that adoptively
transferred T cells survive and persist in the
xenografts (Figure 1f). Together, these results
confirmed that the omentum can harbour and
support the growth of xenogeneic tumor cells and
tumor-specific T cells.
Preclinical therapeutic efficacy of
adoptively transferred tumor-specific T cells
demonstrated using the X-mouse model
TKT R438W cells have been shown in vitro to
recognise antigen (mutated TKT R438W peptide)
specifically and with high avidity. In vitro studies
have also shown evidence of significant
cytotoxicity by these cells towards target cells
expressing endogenously processed and presented
peptide in the context of HLA-A*02:01.19 To test
the therapeutic efficacy of TKT R438W cells in
suppressing the growth of DM6 cells in vivo,
1 9 106 TKT R438W cells were injected i.p. into 5-
day-old xenografts established with either DM6-
Mut cells, which express the antigen (mutated TKT
R438W peptide) in the context of HLA-A*02:01, or
control DM6-WT cells, which express the wild-type
(nonmutated TKT) peptide (Figure 2a). Tumor
burdens were determined post-mortem by
microscopic scanning of omental whole mounts
and quantifying the GFP signal in the omenta.
Comparison of tumor burdens on day 10 (i.e.
5 days following transfer of TKT R438W cells)
revealed significant suppression of DM6-Mut, but
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Figure 1. The Xenomimetic mouse model supports the growth of xenogeneic tumor cells and tumor-specific T cells. (a) 2.5 9 106 DM6-Mut
cells were injected i.p. into NSG mice. The mice were euthanised on days 1, 6, 13 and 20, and the greater omentum was harvested. Tumor
burden was visualised by H&E staining of the omental sections. Scale bar = 200 µm. (b) Tumors are visualised as green (GFP+) areas in omental
whole mounts on day 11. (c, d) Luciferase+ DM6 tumors can be visualised and quantified by live imaging. Xenografts were established using
2.5 9 106 DM6-Mut-LUC+ cells. On different days following the injection of tumors, luciferin was injected and photon flux quantified to
determine tumor burden. Representative images of DM6 tumors on different days are shown in c. Quantified tumor burdens over time (n = 5
mice per group) are shown in d. (e) 5 9 106 TKT R438W cells were injected i.p. into NSG mice. The mice were euthanised on day 6, and the
greater omentum was harvested. A whole mount of the omentum was stained with AlexaFluor 647-conjugated anti-human CD3 and scanned
under a fluorescence microscope. CD3+ T cells are denoted by white arrows. (f) 3 9 106 TKT R438W cells were injected on day 5 into DM6-Mut
xenografts and tumor-specific T cells (TKT R438W) detected on day 25 by identifying binding to peptide-loaded dextramers. Gated on live
CD3+CD8+ cells (n = 4 mice per group).
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not DM6-WT cells (Figure 2b and c),
demonstrating the specificity of TKT R438W cells,
as well as their cytotoxicity in vivo. Upregulation
of the activation marker CD69 on T cells isolated
from day 10 DM6-Mut xenografts confirmed that
these cells are activated upon entry into the
tumor microenvironment (Supplementary
figure 3).
Tumors escape from T-cell control in the X-
mouse model
To determine the durability of this T cell–
mediated tumor suppression, we measured tumor
burdens on day 25 in the above cohorts of mice.
When left untreated, mice with DM6-Mut
xenografts show rapid tumor growth, and by day
25, the tumor burden in the omenta is too high
to be accurately quantified using microscopic
scanning (too high to determine accurately or
THTD). Gross images are shown for these mice
(Figure 2d). Moreover, these mice also develop
peritoneal ascites fluid and metastatic lesions on
the liver, spleen and in the peritoneum. Of
particular importance to our model is our
observation that the initial T-cell suppression of
tumor on day 10 is followed later by a tumor
escape from T-cell control. The tumor escape is
consistently observed by day 25 as evidenced by a
significant increase in tumor burden (Figure 2b
and c). Control untreated DM6-WT xenografts
were grossly indistinguishable from TKT R438W-
treated DM6-WT xenografts on day 25
(Figure 2d).
The escape of tumors following initial
suppression observed in the omentum was also
demonstrated using in vivo imaging to quantify
tumor burdens in the entire mouse (Figure 2e).
Injection of TKT R438W cells on day 5 suppresses
growth of DM6-Mut-LUC+ cells, which begin to
escape the T-cell control by day 23.
Transferring escalating doses of TKT R438W cells
(ranging from 1 9 104 cells to 3 9 106 cells)
resulted in a dose-dependent suppression of
tumor burdens on day 10 (Supplementary figure 4
and Supplementary table 1). However, it could
not prevent the escape of DM6-Mut tumors from
T cell control on day 25, although the degree of
tumor escape inversely correlated with the
numbers of adoptively transferred T cells. This
suggested that tumor recurrence was not simply a
matter of insufficient T-cell numbers, and led us
to predict and test the probability that the tumor
escape from T-cell control may be due in part to
immunosuppressive mechanisms within the
microenvironment of the tumor xenograft.
The X-Mouse model as a tool for preclinical
testing of adoptive T-cell therapy protocols
We postulated that the kinetics of tumor escape
could also be used to determine the efficacy of
altering the adoptive T-cell therapy protocol and
timing of the T-cell transfer. This was tested by
determining whether the tumor escape could be
delayed or prevented by the adoptive transfer of
a combination of T cells specific for different
tumor antigens or by the repeated injection of T
cells specific for one tumor neoantigen. The
answer to these questions would be of potential
value in designing the most therapeutically
effective adoptive cell transfer for cancer patients
using tumor antigen-specific T cells.
We first determined whether the adoptive
transfer of a combination of two T-cell
populations derived from the same patient with
specificity for two different tumor neoantigen
peptides was therapeutically more effective than
injecting the same number of T cells with a single
peptide specificity. To address this, we introduced
similar numbers of T cells with specificities for
different tumor neoantigen peptides (TKT R438W
and TMEM48 F169L) into DM6-Mut xenografts
individually or in combination (Figure 3a). We
found that all three treated groups displayed
early suppression of tumor growth on day 10
(compared to untreated). However, only the
cohort that was given a combination of TKT
R438W and TMEM48 F169L suppressed tumor
recurrence, demonstrating a tumoristatic effect on
day 25, while the TKT R438W as well as the
TMEM48 F169L single treatment groups showed a
2- and 6.6-fold increase in tumor burden,
respectively (Figure 3b and c, and Supplementary
figure 5a). We conclude from these results that
combining T cells with different specificities is
more efficacious and can significantly delay tumor
escape in the X-mouse model.
Next, we tested whether the therapeutic
efficacy of the adoptive cell transfer was
enhanced by repeating the T-cell transfer. To
assess the effect of reintroducing T cells in the
xenograft, 1 9 106 TKT R438W cells were
introduced either on day 5 only (single treated)
or on days 5 and 10 (double treated) into DM6-
Mut xenografts (Figure 3d). Reintroduction of
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TKT R438W cells on day 10 was found to
significantly suppress the tumor escape seen in
the single treated cohort (Figure 3e and f, and
Supplementary figure 5b). These results are
consistent with the loss of T-cell function that has
been reported to occur in tumor
microenvironments, and establish repeated
injections of T cells as a viable strategy to
enhance anti-tumor responses in the X-mouse
model.
Figure 2. Initial suppression of tumor growth following the adoptive transfer of tumor-specific T cells is followed by tumor escape in the X-
mouse model. (a) Experimental scheme indicating the timeline for injection of tumor cells (green arrow), TKT R438W cells (blue arrow) and
estimation of tumor burden (red arrows). (b) Representative images of omental tumor burdens on days 5, 10 and 25. (c) Tumor burdens were
determined by quantifying the GFP signal using ImageJ software and are represented as corrected total fluorescence (CTF). There are no bars for
WT, WT+ and Mut- cohorts on day 25 as they were THTD (n = 3 mice per group). (d) Gross images of omenta on day 25 from different
groups. (e) Xenografts established using 2.5 9 106 DM6-Mut cells were either left untreated, or treated with 1 9 106 TKT R438W cells on day
5. Tumor burden was determined on different days by measuring the photon flux following the i.p. injection of luciferin (n = 5 mice per group).
Data are presented as mean  SEM. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001. THTD = too high to determine accurately.
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Figure 3. Tumor escape is suppressed by combining tumor-specific T cells of different specificities or by repeated injections of T cells. (a, d)
Experimental scheme indicating the timeline for injection of tumor cells (green arrow), TKT R438W cells (blue arrows), TMEM48 F169L cells
(purple arrow) and estimation of tumor burden (red arrows). (b, e) Representative images of omental tumor burdens on day 25. (c, f) Tumor
burdens are represented as corrected total fluorescence (CTF). n = 3 mice per group for a–c and 5 mice per group for d–f. There are no bars for
untreated cohorts on day 25 as they were THTD. Data are presented as mean  SEM. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001. THTD, too high to
determine accurately.
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Taken together, our results establish that the X-
mouse model as a reliable preclinical tool that can
be used to test and optimise protocols for
adoptive cell transfer therapies for cancer
patients.
Tumor escape mechanisms in the X-mouse
model
We next sought to identify and address
mechanisms of tumor escape in the X-mouse
model. Of the multiple immunosuppressive factors
in the tumor microenvironment, prevalent tumor
escape mechanisms in patients include
downregulation of MHC class I, loss of target
peptides recognised by anti-tumor T cells and
checkpoint-mediated downregulation of T-cell
responses in the tumor microenvironment.22 We
did not find any evidence of MHC class I
downregulation in DM6-Mut xenografts
(Supplementary figure 6a). Day 25 DM6-Mut
xenografts also expressed high levels of GFP,
which is a reporter for cells bearing the TMC (and
hence the peptide, since they are driven by the
same promoter), which ruled out any significant
loss (P = 0.662) of tumor antigen (Supplementary
figure 6b).
Adoptively transferred T cells in the X-mouse
model may leave the omental xenografts and
localise to other lymphoid organs/circulation over
time. The detection of antigen-specific CD8+ T
cells in day 25 xenografts (Figure 1f) confirmed
that these cells persist in the omentum for the
duration of our experiments, ruling that out as a
possible reason for tumor escape.
Persistently activated T cells have been reported
to upregulate molecular markers of exhaustion,
such as PD-1, CTLA-4, LAG3 and CD160,22 which
correlate with their dysfunction. Based upon the
assumption that the T cells in the xenograft are
subject to persistent activation by the tumors, we
predicted that the T cells would upregulate these
checkpoint molecules, rendering them
hyporesponsive to activation, and contribute to the
tumor escape. Consistent with this possibility, we
established that TKT R438W cells persistently
activated with the cognate antigen in vitro
upregulated the checkpoint molecules PD-1, CTLA-
4, LAG3 and CD160 (Supplementary figure 7a).
Furthermore, TKT R438W cells isolated from day 10
DM6-Mut xenografts also showed high PD-1
expression (Supplementary figure 7b). PD-1 initiates
immunosuppressive signalling by binding to its
ligand, PD-L1, that is expressed on multiple cell
types in the tumor microenvironment including
tumor cells,23 and is upregulated in response to IFN-
c secreted by activated T cells.24 We found that the
tumor target cells upregulated PD-L1 when exposed
to conditioned media derived from activated TKT
R438W cells (Supplementary figure 7c). We also
confirmed the expression of PD-L1 in tumor
xenografts by immunofluorescence labelling of
omental wet mounts. PD-L1 expression was first
detected on day 15 (data not shown), and PD-L1+
cells were seen in escaping tumors on day 25
(Supplementary figure 7d). No PD-L1+ cells were
detected in xenografts established using only DM6-
Mut cells (Supplementary figure 7d), indicating that
T cells were required for PD-L1 expression in the
xenografts. While these results show the presence
of PD-L1 in DM6-Mut tumor xenografts, a careful
examination of these micrographs reveals that all
tumor cells are not PD-L1+, and does not rule out the
possibility that PD-L1 may be expressed on
nontumor cells such as T cells in the tumor
microenvironment. Collectively, these results
provided a rationale for determining whether the
upregulation of PD-1 on the TKT R438W cells
contributes to the tumor escape observed on day 25.
Preclinical therapeutic efficacy of PD-1
blockade demonstrated using the X-mouse
model
The use of mAb to target the immunosuppressive
PD-1/PD-L1 signalling (checkpoint blockade
therapy) has been used successfully in the clinic,
leading to multiple FDA-approved biologics.25,26
We tested the role of PD-1 in tumor escape in the
X-mouse model by using nivolumab, an FDA-
approved anti-PD1 mAb used in the treatment of
metastatic melanoma.27 The antibody blockade of
PD-1 (Figure 4a) was shown to completely prevent
tumor escape from T cell-mediated suppression on
day 25 (Figure 4b and c), providing confirmation
that PD-1 upregulation contributes to the
observed tumor escape. More importantly, these
results also provide the first validation of the X-
mouse model’s ability to reflect the therapeutic
efficacy of an established immune-based therapy.
Preclinical therapeutic efficacy of IL-12
demonstrated using the X-mouse model
To further credential our model for evaluating
immune-based therapies, we next tested the
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ability of the model to mimic the anticipated
efficacy of another therapy known to enhance T-
cell function in the tumor microenvironment,
interleukin-12. IL-12 encapsulated in multilamellar
liposomes has been found to activate T cells in
tumor microenvironments established in PDX.11
We predicted that introduction of IL-12 into the
X-mouse xenografts would result in an activation
of the T cells that would ultimately result in the
prevention or delay of the tumor escape. To test
this prediction, 20 µg of IL-12 encapsulated into
multilamellar liposomes was injected i.p. into
xenograft-bearing mice (Figure 5a). Control
groups were treated with empty liposomes. We
found that there was a partial suppression of
DM6-Mut tumor escape on day 25 in the IL-12-
treated cohort (Figure 5b and c, and
Supplementary figure 8a), confirming the viability
of this approach. IL-12 had no effect on tumor
burden in DM6-WT xenografts treated with TKT
R438W cells, ruling out nonspecific effects of
either IL-12, or IL-12-activated TKT R438W cells on
control tumor cells.
We next attempted to enhance the observed
therapeutic effect of IL-12 liposomes by their
repeated administration and determine whether
the predicted enhancement of the anti-tumor
response would be reflected in the X-mouse
model. For this, the experiment was designed
similarly, but with additional liposomal IL-12
injections on days 15 and 20 (Figure 5d). DM6-WT
controls were not used since we had already
demonstrated the absence of any detectable
nonspecific effects. We found that by modifying
the schedule, a greater suppression of the tumor
was reflected in the model. This treatment
schedule not only prevented tumor escape, but
also knocked down the tumor burden from day
10 by 50% (Figure 5e and f). Because IL-12-
mediated stimulation of T cells leads to expression
of IFN-c, we tested circulating levels of IFN-c on
day 15 (i.e. 5 days after the first injection of IL-12)
by ELISA.28 Indeed, the mean IFN-c levels were
found to be threefold higher in the cohort that
received IL-12 liposomes compared to the one
that received control liposomes, consistent with
Figure 4. Anti-PD1 treatment suppresses tumor escape in the X-mouse model. (a) Experimental scheme indicating the timeline for injection of
tumor cells (green arrow), TKT R438W cells (blue arrow), treatment with anti-PD1 or isotype control (brown arrows) and estimation of tumor
burden (red arrows). (b) Representative images of omental tumor burdens on day 25. (c) Tumor burdens are represented as corrected total
fluorescence (CTF) on days 5, 10 and 25. There are no bars for untreated cohorts on day 25 as they were THTD. Since the mice that received
TKT R438W cells on day 10 were divided equally and given either the isotype control or anti-PD1, those are the only two cohorts on day 25.
n = 5 mice per group. Data are presented as mean  SEM. **P ≤ 0.01. THTD, too high to determine accurately.
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Figure 5. Liposomally delivered IL-12 suppresses tumor escape in the X-mouse model. IL-12 was delivered once (a–c) or thrice (d–f) to DM6
xenografts. (a, d) Experimental scheme indicating the timeline for injection of tumor cells (green arrow), TKT R438W cells (blue arrow), treatment
with IL-12 liposomes or control liposomes (brown arrows) and estimation of circulating IFN-c (pink arrow) as well as tumor burden (red arrows).
(b, e) Representative images of omental tumor burdens on the days 5, 10 and 25. (c, f) Tumor burdens are represented as corrected total
fluorescence (CTF). n = 3 for a–c and 5 for d–f. There are no bars for untreated DM6-Mut as well as DM6-WT (untreated or treated) cohorts on
day 25 as they were THTD. Since the mice that received TKT R438W cells on day 10 were divided equally and given either the empty (control)
liposomes or the IL-12 liposomes, those are the only two cohorts on day 25. Data are presented as mean  SEM.**P ≤ 0.01. THTD, too high to
determine accurately.
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enhanced T-cell stimulation as a result of IL-12
injection (Supplementary figure 8b). Together,
these results validate our model for its ability to
mimic anticipated results of another immune-
based therapy.
Monitoring the effect of immunotherapy on
patient-derived anti-tumor T cells in the
tumor microenvironment using the X-mouse
model
Ex vivo exposure to IL-12 has been shown to
protect tumor-infiltrating murine CD8+ T cells
from negative regulation by IFN-c via
downregulation of IFNcR2 and PD-1 expression in
a mouse model of melanoma.29 Additionally,
intratumoral electroporation with IL-12 has been
shown to result in a coordinated downregulation
of multiple checkpoints including PD-1 and LAG3
in murine CD8+ T cells.30 We therefore tested
whether IL-12 treatment affected the expression
of the checkpoint molecules PD-1 and LAG3 on
patient-derived anti-tumor T cells in the X-mouse
model. The xenografts for the different
experimental cohorts were established as
described (Figure 6a), and T cells were recovered
from the xenografts by the previously described
walk out method31 at multiple time points. The
expression of PD-1 and LAG3 on T cells (CD3+ cells
gated as shown in Supplementary figure 9) was
determined by flow cytometry. Following their
entry into the DM6-Mut xenograft, PD-1
expression on TKT R438W cells was initially
upregulated by about sixfold on day 10
(Figure 6b), that is 5 days following T-cell
injection, as observed earlier (Supplementary
figure 7b). These levels continued to increase,
peaking at day 22 with over 55-fold increase over
pre-injection levels (Figure 6b). Injection of IL-12
liposomes suppressed this upregulation at all the
time points studied (Figure 6b). LAG3 expression
followed slightly different kinetics, with
upregulation seen only at time points beyond day
13, while also peaking at day 22 (Figure 6c). As
observed in the case of PD-1, IL-12 was found to
suppress the upregulation of LAG3 at all the time
points studied (Figure 6c). We show here for the
first time, the ability of IL-12 immunotherapy to
suppress the upregulation of checkpoint
molecules in patient-derived anti-tumor T cells in
the tumor microenvironment.
Taken together, these data establish that the X-
mouse model is a powerful preclinical tool for
rapidly evaluating immunotherapy protocols by
monitoring changes in the tumor burden as well
as in the phenotype of tumor-specific T cells at
the cellular level.
DISCUSSION
As the first tumor xenograft model to provide a
controlled system in which the number of tumor
cells used to establish tumor xenografts is known,
the timing and number of T cells that are
adoptively transferred into tumor-bearing mice
are controlled, and the tumor specificity of the T
cells for tumor antigens is well-defined, the X-
mouse model offers several advantages over
existing PDX models. The DM6 cell line was
selected for our study as it is an established
melanoma model for immunotherapy with high
clinical relevance. Additionally, the HLA type of
DM6 cells was compatible with that of the
patients in the neoantigen vaccination trial. This
ensures that once the cells are transduced with
cells with TMC with the mutated tumor peptides,
these peptides are processed and presented in the
context of MHC-I on their surface, turning the
DM6-Mut cells into target cells that are
recognised and killed by the patient’s tumor-
specific T cells. With this approach, we have
established the presence of multiple tumor
antigen-specific T cells in three different
vaccinated patients. We have also demonstrated
the utility of our model using melanoma cells
expressing two different patient tumor-derived
neoantigen peptides (TKT R438W and TMEM48
F169L) and the T cells that recognise these
peptides. The use of DM6-WT tumors, where the
tumor cells express the nonmutated/wild-type
peptide which differs from the neoantigen
peptide by only one amino acid, provides an
elegant control, and the failure of the adoptively
transferred T cells to suppress these tumors
establishes the specificity of the anti-tumor
response in our model. High T-cell yields
following expansion (3.6–10.8 9 108 cells per
neoantigen, Supplementary figure 1b), coupled
with relatively low T-cell number requirements to
establish an X-mouse xenograft (0.5–1 9 106),
translate into at least 300–1000 xenografts per
antigen-specific T-cell population. The X-mouse
model has made it possible to obtain and
quantify at intervals, changes in the number,
phenotype and function of the T cells in the
tumor microenvironment with and without
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therapy, as well as to demonstrate the ability of
the tumor to escape the T-cell response and
metastasise, thereby providing a distinct
advantage over simple in vitro co-culture systems
for preclinically evaluating the efficacy of
immune-based therapies.
Our use of GFP and/or luciferase represents an
accurate and highly sensitive way for quantifying
tumor burden in the X-mouse model, providing
advantages over existing methods such as
measurement of tumor volume using callipers,
which does not distinguish between tumor,
stromal and immune cells, in addition to being
error prone32; and the detection of tumor
transcripts,33 which involves multiple processing
steps that can be time-consuming as well as
labour-intensive. GFP allows rapid measurement
of tumor burden post-mortem by scanning wet
mounts of the omental tissue directly under the
fluorescent microscope without any need for
processing or immunofluorescence labelling.
While using GFP as a marker of tumor burden
does have some limitations such as its relatively
low permeability through tissue—a problem that
Figure 6. IL-12 suppresses the upregulation of checkpoint molecules in TKT R438W cells. (a) Experimental scheme indicating the timeline for
injection of tumor cells (green arrow), TKT R438W cells (blue arrow), treatment with IL-12 liposomes or control liposomes (brown arrows) and
estimation of tumor burden (red arrows). Kinetics of PD-1 (b) and LAG3 (c) expression in TKT R438W cells following their entry into DM6-Mut
tumor xenografts in different experimental cohorts are shown. Mice were euthanised on the indicated days, and T cells derived from the omenta
were analysed by flow cytometry. Gated on CD3+ cells as shown in Supplementary figure 9. Data (n = 3 mice per group) represented as
mean  SEM. ***P ≤ 0.001.
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is aggravated by stromal thickening during tumor
growth—this is considerably offset in the X-mouse
model because of the translucent nature of the
omentum, which is the primary site of the
xenograft. The sensitivity of the X-mouse model
can be improved upon in future iterations by
replacing GFP with red and far-red-emitting
proteins that have better tissue penetration and
consequently lesser loss of signal. While end-stage
GFP quantification is lacking in this study because
of high tumor burden in the omenta which makes
the signal THTD, further optimisation of exposure
times to enable the measurement of GFP signal
over a wider spectrum is expected to overcome
this. Luciferase is useful for in vivo monitoring of
the tumor burden and particularly to track
metastasis.34 Further, it may be used for ex vivo
monitoring of omental tumor burden at the
terminal time point, providing another means to
overcome the lack of end-stage tumor
quantification.
The rapid and preferential localisation of both
the melanoma tumor target cells and the tumor-
specific T cells into the greater omentum in our
model has made it possible to recover and quantify
changes at the cellular level in the number and
phenotype of the tumor cells within the xenograft
and in the number, phenotype and function of the
anti-tumor T cells following their entry into the
tumor microenvironment. While we recognise that
the omentum is not a natural or preferential site of
metastasis for melanomas in patients, ovarian
tumors naturally metastasise to the omentum in
patients,35,36 and many different types of human
tumors engraft rapidly and preferentially in the
greater omentum of mice,9,21 making it an ideal
anatomical location for establishing human tumor
xenografts. Another unique and significant
advantage of the X-mouse is the rapid engraftment
of tumors that have made it possible to generate
results within just 25 days for post-mortem studies
and tumor progression but can potentially be
monitored continuously for longer periods using
live imaging of mice.
Although adoptive cell therapy has made huge
strides in cancer treatment, especially with the
emergence of CAR T cells, tumor relapse/
recurrence is common37 and remains a challenge.
The escape of DM6-Mut tumors following the
initial adoptive transfer of tumor-specific T cells is
critical to our model as it allows us to test
immune-based therapies designed to enhance
anti-tumor T-cell activity of adoptively transferred
T cells by monitoring their ability to prevent or
delay the tumor escape. Our discovery of the
involvement of the PD-1/PD-L1 axis in the X-
mouse xenografts allowed us to test two immune-
based therapies that target this
immunosuppressive mechanism. First, we
demonstrated that checkpoint blockade using
nivolumab, an FDA-approved anti-PD-1 antibody
that is currently used in the clinic, was able to
suppress tumor escape in the X-mouse model,
validating our model for immunotherapeutic
testing. The second immune-based therapy that
we tested, IL-12, is predicted to enhance anti-
tumor T-cell response by two mechanisms:
stimulating T cells directly through its receptor IL-
12R and by protecting T cells from IFN-c mediated
negative regulation by downregulating
checkpoint expression. As expected, not only did
treatment with IL-12 result in enhanced anti-
tumor response as seen by the suppression of
tumor escape, it also resulted in the suppression
of PD-1 and LAG3 upregulation, providing further
credentialing of the X-mouse model. The ability
to monitor checkpoint kinetics in response to
immune therapies in patient-derived tumor-
specific T cells is a unique and unmatched feature
of the X-mouse model. We thus establish the
potential of the model to reflect/mimic the
predicted enhanced anti-tumor responses of the
adoptively transferred T cells in response to
immune-based therapies.
One of the major characteristics that set the X-
mouse model apart from other PDX models is that
the adoptively transferred T cells are the only
immune competent cells in the xenograft. While this
may be considered a limitation for certain
applications, it also provides us with a distinct
advantage. Enhanced anti-tumor activity seen as a
response to any immunotherapy being tested in the
X-mouse model will be a result of directly affecting
the dynamic between tumor cells and T cells, making
the interpretation of results far less complicated than
it would be in the presence of other immune cells in
the microenvironment. Therefore, our model is best
suited to test immunotherapies that are designed to
enhance T-cell function and is expected to aid in
rapid go/no-go decisions at the preclinical stage of
development.
While we establish the feasibility of the X-mouse
model here using DM6 cells, we recognise the need
to include more tumor cell lines to demonstrate the
robustness of our model and its broad applicability.
The use of a single tumor cell line also has the
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additional limitation of not being able to
recapitulate the diversity of mutational profiles that
occur in tumors from different patients. We plan to
overcome this by generating additional tumor
target cells derived from the patient’s tumor in the
future. We also plan to investigate the role of
additional immune checkpoints such as other
exhaustion markers (CTLA-4, Tim-3 and CD160),
tumor-associated exosomes38–40 as well as exosome-
associated immunosuppressive lipids such as
phosphatidylserine41 and ganglioside GD342,43 in
the observed tumor escape in future studies. The
efficacy of checkpoint blockade can also be
enhanced many fold with combination therapy,
which can be tested rapidly in our model. As the
only existing model that can preclinically evaluate
the efficacy of immune-based therapies using
patient-derived tumor-specific T cells, we believe
that harnessing the potential of the X-mouse model




Patients with stage III cutaneous resected melanoma were
enrolled in a phase 1 clinical trial with autologous,
functionally mature, interleukin-12p70 (IL-12p70)–producing
dendritic cell vaccine. Exome sequencing was performed to
identify somatic mutations in surgically excised tumor
samples. Tumor missense mutations, translated as amino
acid substituted nonamer peptides, were filtered through in
silico analysis to determine HLA-A*02:01 peptide-binding
affinity. Selected peptides from validated HLA-A*02:01
binders were incorporated into a personalised vaccine
formulation. Neoantigen-specific CD8+ T cells were
identified by dextramer assay directly in postvaccine PBMC
samples. CD8+ T cells specific for two neoantigens—TKT
R438W (TKT) and TMEM48 F169L (TMEM) in patient MEL21
—were expanded from leukapheresis products and used for
this study (Supplementary figure 1b).
Tumor target cell generation
DM6, an HLA-A*02:01+ melanoma cell line, was transfected
with TMCs and serves as a target for in vivo presentation of
neoantigens, TKT R438W and TMEM48 F169L or wild-type
counterparts. TMC consisting of 7–10 minigenes cloned into
pMX vector (GFP+), expressed as retrovirus and used to
transduce the HLA-A*02:01+ melanoma line DM6. The TMC as
well as the GFP is driven by the cytomegalovirus immediate
early promoter. Each minigene encoded an amino acid
substituted, or the corresponding wild-type amino acid,
embedded in 19–21 amino acids derived from the normal
gene product. Both TMEM48 F169L and TKT R438W were
processed and presented, as evidenced by cytotoxic activity
and IFN-c production by corresponding neoantigen-specific T
cells upon co-culture with DM6 cells expressing mutated
neoantigens (DM6-Mut) but not wild-type-encoding TMCs
(DM6-WT). DM6-WT and DM6-Mut luciferase-expressing cells
(DM6-WT-LUC+ and DM6-Mut-LUC+) were generated by
retroviral transduction followed by neomycin selection.
Cell culture
DM6-Mut and DM6-WT cells were maintained in RPMI-1640
supplemented with 10% heat-inactivated FBS, 2 mM
L-glutamine, 20 U mL1 penicillin, 20 µg of streptomycin
and 50 µM 2-mercaptoethanol (complete medium) at 37°C
under 5% CO2. Cells are adherent and were grown in 75- or
175-cm3 flasks until they were 90% confluent. For cell
harvesting, cultures are treated with 0.25% trypsin–EDTA
for 3–4 min at 37°C following removal of the medium and
one wash with phosphate-buffered saline (PBS). Complete
medium is added to stop the reaction and cells are
centrifuged at 300 g for 10 min.
Authentication of cell lines
The parental DM6 cell line was obtained from Dr Hilliard
Seigler at Duke University. The identity of the cell line has
been confirmed by concordance between reported and
tested HLA class I typing. DM6 cells were molecularly HLA
typed using next-generation sequencing and assignments of
HLA-A and HLA-B alleles corroborated those reported in the
Expasy database (www.expasy.org). DM6 cells were
transduced with retroviruses encoding the TMC, Rho C and
click beetle green luciferase and/or green fluorescent
protein (GFP). These cells were selected based on GFP
expression (> 99% GFP-positive) and expanded. Cells were
cultured in complete DMEM media and periodically
monitored for transgene expression. Banks of the above-
engineered DM6 cells were also screened and confirmed to
be free of mycoplasma contamination. The cells from any
one cryopreserved vial were not passaged for more than
2 months after being thawed out. These cells were tested
for GFP expression and confirmed to be > 99% positive on
the day of the experiments.
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl, abbreviated NSG mice (young
adult females 8–12 weeks old), raised in a research colony
at the Jackson Laboratory (Bar Harbor, ME, USA), were used
for this study. The sample size for in vivo experiments was
calculated based on the ability to demonstrate with 85%
power, a 2-fold difference in tumor burden, allowing for a
30% standard deviation in tumor size and spread assuming
a normal distribution of the samples. Age- and sex-matched
mice were assigned to control and test groups.
Establishment of xenografts
NSG mice were implanted with 2.5 9 106 DM6-Mut or DM6-
WT cells i.p. in a total volume of 0.5 mL. Cryopreserved
neoantigen-specific TKT R438W or TMEM48 F169L cells
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were thawed and incubated in complete medium for 6 h at
37°C and 5% CO2. Unless noted otherwise, 5 9 10
5 or
1 9 106 T cells were injected i.p. per mouse in a total
volume of 0.5 mL, 5 days following the implantation of
DM6 cells. While the experiments demonstrating the in vivo
efficacy of anti-PD1 (Figure 4) and IL-12 (with three
treatments, Figure 5d–f) were set up at the same time and
therefore shared day 5 and 10 controls, all other xenografts
were set up independently. All experiments were
independently repeated at least once, and data from a
representative experiment are shown. All animal studies
were approved by the Institutional Animal Care and Use
Committee.
Post-mortem analysis of tumor burden
Twenty-five days following tumor implantation, the mice
were euthanised and the greater omentum from each
mouse was surgically removed. A wet mount of the
omentum in PBS was scanned using the Leica DM6 B
upright fluorescence microscope (Leica Microsystems,
Wetzlar, Germany). The entire omentum was scanned under
the 59 objective using the GFP and DIC filters. The images
were exported as TIF files and analysed using ImageJ
software (National Institutes of Health, Bethesda, MD, USA)
to quantify the GFP signal. The polygon tool was used to
draw a tight border around the omentum, and the amount
of signal was measured in the green channel. Background
in the green channel was also measured by drawing a gate
in a region of the omentum that was free of any tumor
cells. Corrected total fluorescence was then calculated using
the formula CTF = intensity density of omentum  (area of
omentum 9 mean grey value of background for that
omentum).
In vivo analysis of tumor burden
Tumor cells were implanted in the omentum as described
above. Local and disseminated tumor burden was
monitored by bioluminescent imaging. Mice were
anaesthetised with 4% isoflurane and injected i.p. with
substrate D-luciferin (Gold BioTechnology #LUCK-1G, St.
Louis, MO, USA) at 150 mg kg1 in Dulbecco’s PBS and,
after a 5-min interval, were placed onto the warmed stage
inside the light-tight camera box of the imager (IVISTM
Spectrum; Perkin Elmer, Waltham, MA, USA) while under
2% isoflurane. Light emitted from bioluminescent cells was
recorded by the IVIS camera system. Images were
quantified for tumor burden using a log-scale colour range,
and measurement of total photon counts per second (p/s)
was determined using Living Image software (Perkin Elmer).
Recovery of T cells from xenografts
T cells were recovered from the omenta of xenograft-
bearing mice by the previously described walkout
method.31 Omenta were harvested under sterile conditions
and placed in complete medium in wells of a 6-well tissue
culture plate. The omenta were gently cut into small 4- to
5-mm pieces and incubated overnight at 37°C under 5%
CO2. On the following day, the medium with the ‘walkout
cells’ was passed through a 70-µm cell strainer to exclude
omental tissue and debris.
Histology
Fresh tissue was fixed in 10% neutral-buffered formalin and
processed for paraffin embedding. SUNY Buffalo Histology
Service Laboratory performed the H&E staining of the
omental tissue.
Checkpoint blockade therapy
10 mg kg–1 of nivolumab (OPDIVO), a humanised anti-PD1
antibody (Bristol-Myers Squibb, East Syracuse, NJ, USA), or
human IgG4 isotype control (Crown Bioscience, San Diego,
CA, USA), was administered i.p. in a total volume of 200 µL
per mouse on days 10, 15 and 20.
Preparation and administration of IL-12
liposomes
IL-12 liposomes were prepared as previously described.10
Large multilamellar liposomes were prepared by
rehydrating the lipid film of appropriate molar ratios of
distearoyl phosphatidylcholine (DSPC), dimyristoyl
phosphatidylglycerol (DMPG) and cholesterol (CHOL)
(DSPC∶DMPG∶CHOL; 50∶50∶25) with phosphate buffer
containing recombinant human IL-12 at 45°C. The
spontaneous loading of a large complex molecule such as
IL-12 is accomplished by a mild denaturation of IL-12 to
partially and reversibly unfold the protein to expose
hydrophobic domains resulting in the intercalation of the
cytokine within or between the lipid bilayers of the
liposomes. This technique called triggered loading results in
an optimal loading of the IL-12 which retains its biological
activity. After rehydration, lipids are gently swirled and
incubated at 45° for 20 min. 20 µg of IL-12 liposomes or
empty (control) liposomes was administered to mice i.p. in
a total volume of 500 µL on day 10.
Flow cytometry
Immunofluorescence labelling was performed as described
previously38 using fluorochrome-conjugated antibodies and
reagents are listed in Supplementary table 2. Briefly, 1 9 106
cells were set up in each tube in PBS for immunofluorescence
labelling. The cells were blocked with normal mouse IgG for
10 min, and directly labelled antibodies were added and
incubated on ice for 30 min. In experiments where MHC
Dextramer reagents were used to detect antigen-specific T
cells, they were added to the tubes 10 min prior to the
addition of the antibodies. Sytox Red was added 15 min
before flow cytometry at a final concentration of 5 nM to label
the dead cells. Samples were acquired on an LSR Fortessa (BD
Biosciences, San Jose, CA, USA) flow cytometer. A minimum of
2 9 104 lymphocytes were acquired for analysis of T cells from
xenografts, and for other studies, data acquisition was
stopped after acquiring 5 9 104 lymphocytes. Data analysis
was performed using FlowJo software (Tree Star Inc., Ashland,
OR, USA).
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PD-L1 expression in conditioned media
DM6-Mut cells were plated onto 6-well plates and grown to
60–80% confluency for 48 h. TKT R438W T cells were then
added in fresh media at a ratio of 1:1.5 (tumor cell:T cell) and
incubated for an additional 48 h. Media was collected, and
cells and debris were pelleted by centrifugation at 1150 x g
for 5 min. Supernatant was collected and added at varying
dilutions to new DM6-Mut cells grown to ~50% confluency.
These T-cell conditioned media-treated DM6-Mut cells were
grown for an additional 48 h before protein was collected
and probed for PD-L1 expression bywestern blot.
Western blots
Cell protein was harvested using RIPA buffer (G Biosciences,
St. Louis, MO, USA) supplemented with Halt protease
inhibitor (Thermo Fisher Scientific, Grand Island, NY, USA).
Protein concentration was measured using the DC protein
assay (Bio-Rad, Hercules, CA, USA). Electrophoretic
separation of protein (12–20 lg/well) was performed using
4–15% gradient polyacrylamide gels (Bio-Rad). Separated
protein was transferred onto PVDF membranes (Bio-Rad),
which were then blocked for 1 h at room temperature in
Tris-buffered saline containing 0.1% tween (TBS-T) with 5%
fat-free milk (Bio-Rad), followed by overnight incubation at
4°C with rabbit anti-human PD-L1 antibody (Cell Signaling
Technologies, #13684T, Danvers, MA, USA) (1:1000 dilution)
or mouse anti-human b-actin antibody (1:10 000 dilution)
(Cell Signaling Technology, #3700 S) in 5% fat-free milk
with TBS-T. Membranes were washed in TBS-T and
incubated for 20 min at room temperature with a 1:2000
dilution of horseradish peroxidase-conjugated goat anti-
rabbit antibody (Promega, #W4011, Madison, WI, USA) or
rabbit anti-mouse antibody (Cell Signaling Technology,
#7076 S) in 5% milk with TBS-T. Protein signals were
developed using the WesternBright ECL HRP substrate
(Advansta, #K-12045, San Jose, CA, USA) and measured
using a Chemi-Doc MP scanner (Bio-Rad).
In vivo detection of PD-L1 by
immunofluorescence labelling of omental
whole mounts
The greater omentumwas surgically removed and transferred
to polypropylene tubes containing PBS. For blocking
nonspecific binding, normal mouse IgG was added and
incubated for 10 min with rocking. Brilliant Violet 421-
labelled anti-PD-L1 (BioLegend, #329714, San Diego, CA, USA)
was added and incubated for 2 h with rocking at 4°C. Samples
were washed twice in PBS for 15 min each and mounted on a
slide. Images were acquired using a Leica DM6 B upright
fluorescence microscope (Leica Microsystems, Wetzlar,
Germany) and analysed using ImageJ software.
Human Interferon Gamma ELISA
A sandwich ELISA for the detection of human IFN-c in mouse
serum was performed as previously described.28 Briefly, 96-well
plates were coated using a mAb to IFN-c (ThermoFisher
Scientific, #M-700-A, Grand Island, NY, USA). Mouse sera were
added to the plate coated with biotinylated monoclonal anti-
human IFN-c (ThermoFisher Scientific, #M-700-B). Positive
binding was detected using streptavidin-conjugated HRP
(Sigma-Aldrich, #A3151, St. Louis, MO, USA), peroxide and
3,30,5,50-tetramethylbenzidine (Kirkegaard & Perry
Laboratories, #52-00-01, Gaithersburg, MD, USA). Results were
measured on a MultiSkan EX automated microplate reader
(Thermo Electron Corporation, Waltham, MA, USA) at OD450–
540 and analysed by comparison with a recombinant IFN-c
standard using SigmaPlot software (Systat Software Inc., San
Jose, CA, USA).
Statistics
All statistics were calculated using GraphPad (GraphPad
Software, San Diego, CA) or Excel 2013 (Microsoft
Corporation, Redmond, WA). Paired or unpaired Student’s
t-tests were applied to determine whether the differences
between groups could be considered significant. A P-value
higher than 0.05 was not significant (ns) while *P ≤ 0.05;
*P ≤ 0.01 and ***P ≤ 0.001 were considered significant.
Study approval
The study was approved by the Institutional Review Board
(protocol MODCR00004766), and all animal experiments were
approved by the Institutional Animal Care and Use Committee
(protocolMIC17072Y) at the University at Buffalo.
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